Sign in Subscribe
Stocks

Annovis Bio Announces Definitive Agreements for Registered Direct Offering

Strategic Insights

— 1 min read

Annovis Bio, a clinical drug platform company focused on transformative therapies for neurodegenerative diseases, has entered into definitive agreements for the purchase of 1,670,732 shares of its common stock through a registered direct offering. The Company's Chairman, Michael Hoffman, and CEO, Dr. Maria Maccecchini, have participated in the offering, which is expected to generate approximately $3.4 million in gross proceeds. The net proceeds will be used towards working capital and general corporate purposes. The securities are being offered and sold through a prospectus supplement, which will be filed with the Securities and Exchange Commission.

Key Takeaways:

  • Annovis Bio has entered into definitive agreements for the purchase of 1,670,732 shares of its common stock at a purchase price of $2.05 per share.
  • The closing of the offering is expected to occur on or about October 28, 2025, subject to the satisfaction of customary closing conditions.
  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
  • The Company intends to use the net proceeds from the offering towards working capital and general corporate purposes.
  • The offerings are being made only by means of a prospectus supplement that forms a part of the registration statement, which was declared effective by the SEC on February 12, 2024.
  • The base prospectus has been previously filed with the SEC on February 1, 2024.
  • The securities are being offered and sold through a prospectus supplement, which will be filed with the SEC.

Statistics:

  • 1,670,732 shares of common stock will be purchased by the Company through the registered direct offering.
  • The purchase price per share is $2.05.
  • The gross proceeds from the offering are expected to be approximately $3.4 million.
  • The Company intends to use the net proceeds of approximately $3.2 million towards working capital and general corporate purposes.

Sources:

  • GLOBE NEWSWIRE, "Annovis Bio, Inc. (NYSE: ANVS) - Annovis Bio Announces Definitive Agreements for Registered Direct Offering" (October 27, 2025)
  • NYSE, "Annovis Bio, Inc. (NYSE: ANVS)" (October 24, 2025)
  • Securities and Exchange Commission (SEC), "Registration Statement on Form S-3 (Registration No. 333-276814)" (February 12, 2024)

Read more